open access
Does ticagrelor effectively inhibit platelets in patients undergoing mild therapeutic hypothermia or it does not?


- Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
open access
Abstract
Editorial without abstract
Abstract
Editorial without abstract
Keywords
ticagrelor, platelet inhibition, hypothermia


Title
Does ticagrelor effectively inhibit platelets in patients undergoing mild therapeutic hypothermia or it does not?
Journal
Issue
Article type
Editorial
Pages
537-539
Published online
2022-07-04
Page views
4243
Article views/downloads
410
DOI
Pubmed
Bibliographic record
Cardiol J 2022;29(4):537-539.
Keywords
ticagrelor
platelet inhibition
hypothermia
Authors
Jacek Kubica


- Szczerbinski S, Ratajczak J, Lach P, et al. Epidemiology and chronobiology of out-of-hospital cardiac arrest in a subpopulation of southern Poland: A two-year observation. Cardiol J. 2020; 27(1): 16–24.
- Szczerbiński S, Ratajczak J, Jasiewicz M, et al. Observational analysiS of out-of-hospital Cardiac Arrest occurRence and temporal variability patterns in subpopulation of southern POLand from 2006 to 2018: OSCAR-POL registry. Cardiol J. 2021 [Epub ahead of print].
- Berdowski J, Berg RA, Tijssen JGP, et al. Global incidences of out-of-hospital cardiac arrest and survival rates: Systematic review of 67 prospective studies. Resuscitation. 2010; 81(11): 1479–1487.
- Nadolny K, Bujak K, Kucap M, et al. The Silesian Registry of Out-of-Hospital Cardiac Arrest: Study design and results of a three-month pilot study. Cardiol J. 2020; 27(5): 566–574.
- Borkowska MJ, Smereka J, Safiejko K, et al. Out-of-hospital cardiac arrest treated by emergency medical service teams during COVID-19 pandemic: A retrospective cohort study. Cardiol J. 2021; 28(1): 15–22.
- Szczerbiński S. Observational, retrospective analysis of the circadian variability of out-of-hospital cardiac arrest within days of the week. Med Res J. 2020.
- Nadolny K, Szczerbiński S, Ładny J, et al. Out-of-hospital cardiac arrest and COVID-19 pandemic. Med Res J. 2021; 6(2): 83–85.
- Ratajczak J, Łach P, Szczerbiński S, et al. Atmospheric conditions and the occurrence of out-of-hospital cardiac arrest in Poland — preliminary analysis of poorly understood phenomena. Med Res J. 2018; 3(3): 121–126.
- Kołtowski Ł, Średniawa B, Tycińska A, et al. Predicting survival in out-of-hospital cardiac arrest patients undergoing targeted temperature management: The Polish Hypothermia Registry Risk Score. Cardiol J. 2021; 28(1): 95–100.
- Freund B, Kaplan PW. A review of the utility of a hypothermia protocol in cardiac arrests due to non-shockable rhythms. Cardiol J. 2017; 24(3): 324–333.
- Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002; 346(8): 557–563.
- Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002; 346(8): 549–556.
- Kozinski M, Pstragowski K, Kubica JM, et al. ACS network-based implementation of therapeutic hypothermia for the treatment of comatose out-of-hospital cardiac arrest survivors improves clinical outcomes: the first European experience. Scand J Trauma Resusc Emerg Med. 2013; 21: 22.
- Nielsen N, Wetterslev J, Cronberg T, et al. Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med. 2013; 369(23): 2197–2206.
- Ratajczak J, Łach P, Umińska JM, et al. Mild therapeutic hypothermia after out-of-hospital cardiac arrest: What does really matter? Cardiol J. 2021; 28(2): 293–301.
- Kubica J, Pstrągowski K, Adamski P, et al. Mild therapeutic hypothermia for patients with acute coronary syndrome and cardiac arrest treated with percutaneous coronary intervention (UNICORN). The design and rationale for the prospective, observational, multicenter study. Med Res J. 2016; 1(1): 23–27.
- Pstrągowski K, Koziński M, Jabłoński M, et al. Optymalizacja postępowania w nagłym pozaszpitalnym zatrzymaniu krążenia w przebiegu ostrego zawału serca — opis przypadku i przegląd piśmiennictwa. Folia Cardiologica. 2011; 6: 27–276.
- Umińska JM, Buszko K, Ratajczak J, et al. Comparison of temperature measurements in esophagus and urinary bladder in comatose patients after cardiac arrest undergoing mild therapeutic hypothermia. Cardiol J. 2020; 27(6): 735–741.
- Klimczuk T, Kubica J, Kasprzak M, et al. Łagodna hipotermia terapeutyczna po nagłym zatrzymaniu krążenia w przebiegu ostrego zespołu wieńcowego – doświadczenia z wdrażania metody. Folia Cardiologica. 2015; 10(1): 19–24.
- Kubica A. Rationale of cardiopulmonary resuscitation training as an element of multilevel educational and motivational project (MEDMOTION). Disaster Emerg Med J. 2020.
- Umińska J, Koziński M, Pstrągowski K, et al. Platelet reactivity during mild therapeutic hypothermia in patients with acute myocardial infarction treated with ticagrelor: study protocol of a single-centre study. Med Res J. 2017; 1(4): 115–119.
- Kubica J, Adamski P, Paciorek P, et al. Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated experts' standpoint. Cardiol J. 2018; 25(3): 291–300.
- Kubica J. The optimal antiplatelet treatment in an emergency setting. Folia Medica Copernicana. 2014; 2(3): 73–76.
- Trąbka-Zawicki A, Tomala M, Zeliaś A, et al. Adaptation of global hemostasis to therapeutic hypothermia in patients with out-of-hospital cardiac arrest: Thromboelastography study. Cardiol J. 2019; 26(1): 77–86.
- Umińska JM, Ratajczak J, Buszko K, et al. Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. Cardiol J. 2020; 27(6): 780–788.
- Ibrahim K, Christoph M, Schmeinck S, et al. High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation. 2014; 85(5): 649–656.
- Kander T, Dankiewicz J, Friberg H, et al. Platelet aggregation and clot formation in comatose survivors of cardiac arrest treated with induced hypothermia and dual platelet inhibition with aspirin and ticagrelor; a prospective observational study. Crit Care. 2014; 18(5): 495.
- Schoergenhofer C, Hobl EL, Staudinger T, et al. Prasugrel in critically ill patients. Thromb Haemost. 2017; 117(8): 1582–1587.
- Liu Y, Kang S, Li X, et al. Modified ticagrelor loading doses according to the vasodilator-stimulated phosphoprotein phosphorylation index improve the clinical outcome in ST-elevation myocardial infarction patients with high on-treatment platelet reactivity. Cardiol J. 2021 [Epub ahead of print].
- Niezgoda P, Barańska M, Adamski P, et al. Influence of METHoxyflurane on ANtiplatelet Effect of ticagrelor in patients with unstable angina pectoris: Rationale and a protocol of a randomized clinical METHANE-SIRIO 4 study. Cardiol J. 2022; 29(2): 324–328.
- Kubica J, Adamski P, Gorog DA, et al. Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. Cardiol J. 2022; 29(1): 148–153.
- Penela D, Magaldi M, Fontanals J, et al. Hypothermia in acute coronary syndrome: brain salvage versus stent thrombosis? J Am Coll Cardiol. 2013; 61(6): 686–687.
- Tomala MT, Trąbka-Zawicki A, Machnik A, et al. Ticagrelor effectively inhibits platelet aggregation in comatose survivors of cardiac arrest undergoing primary percutaneous coronary intervention treated with mild therapeutic hypothermia. Cardiol J. 2021 [Epub ahead of print].
- Umińska JM, Ratajczak J, Pstrągowski K, et al. The impact of mild therapeutic hypothermia on platelet reactivity in comatose survivors of cardiac arrest with acute myocardial infarction treated with ticagrelor. Cardiol J. 2022 [Epub ahead of print].